Literature DB >> 12713988

The role of angiogenesis in vulvar cancer, vulvar intraepithelial neoplasia, and vulvar lichen sclerosus as determined by microvessel density analysis.

Jamna Saravanamuthu1, Wendy M N Reid, David S t George, Julie C Crow, Kerstin J Rolfe, Allan B MacLean, Christopher W Perrett.   

Abstract

OBJECTIVES: We compared microvessel density (MVD) in normal, benign, preneoplastic, and neoplastic (squamous cell carcinoma (SCC)) vulvar disease to ascertain if this parameter could identify cases with lichen sclerosus (LS) and high-grade vulvar intraepithelial neoplasia (VIN3) at risk of developing malignancy.
METHODS: Microvessels were immunohistochemically stained in paraffin wax-embedded vulvar tissue sections with anti-von Willebrand factor (vWF) antibody using the streptavidin-biotin-horseradish peroxidase complex technique. Three "hot spots" with the greatest MVD were identified within 200 microm of the subepithelial dermis under low magnification (x 40 and x 100). The highest (HVD) and average (AVD) MVDs were quantified for each sample under high magnification (x 200) using an image analysis system.
RESULTS: HVD and AVD showed similar significant differences. SCC had significantly the highest MVD followed by VIN3, normal vulva, and LS. LS had significantly the lowest MVD, even lower than that of normal vulva. Two cases of VIN3 had much higher HVD (9.16 and 9.61) and AVD (6.89 and 7.71) compared with the main cluster of cases.
CONCLUSION: In vulvar LS, MVD, as assessed by HVD/AVD, is not a useful parameter in determining potential malignant progression, while in VIN3 this parameter could be valuable in identifying cases at greatest risk of progression to invasive disease.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12713988     DOI: 10.1016/s0090-8258(03)00055-6

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  7 in total

Review 1.  Molecular pathways in vulvar squamous cell carcinoma: implications for target therapeutic strategies.

Authors:  Simona Maria Fragomeni; Frediano Inzani; Anna Fagotti; Luigi Della Corte; Stefano Gentileschi; Luca Tagliaferri; Gian Franco Zannoni; Giovanni Scambia; Giorgia Garganese
Journal:  J Cancer Res Clin Oncol       Date:  2020-04-25       Impact factor: 4.553

2.  Angiogenesis in Paget's Disease of the Vulva and the Breast: Correlation with Microvessel Density.

Authors:  Patricia E Ellis; Allan B Maclean; L F Wong Te Fong; Julie C Crow; Christopher W Perrett
Journal:  J Oncol       Date:  2012-03-26       Impact factor: 4.375

3.  Extramammary Paget disease of the vulva: immunohistochemical analysis of neoangiogenesis and epithelial-mesenchymal transition markers expression.

Authors:  Lara Alessandrini; Nicolò Clemente; Tiziana Perin; Giorgio Giorda; Vincenzo Canzonieri; Francesco Sopracordevole
Journal:  Diagn Pathol       Date:  2018-01-03       Impact factor: 2.644

4.  Plexin D1 is ubiquitously expressed on tumor vessels and tumor cells in solid malignancies.

Authors:  Ilse Roodink; Kiek Verrijp; Jos Raats; William P J Leenders
Journal:  BMC Cancer       Date:  2009-08-25       Impact factor: 4.430

5.  Primary tumor vascularity, HIF-1α and VEGF expression in vulvar squamous cell carcinomas: their relationships with clinicopathological characteristics and prognostic impact.

Authors:  Hari Prasad Dhakal; Jahn M Nesland; Mette Førsund; Claes G Trope; Ruth Holm
Journal:  BMC Cancer       Date:  2013-10-29       Impact factor: 4.430

Review 6.  Autologous lipoaspirate as a new treatment of vulvar lichen sclerosus: A review on literature.

Authors:  Nanouk van der Sluis; Esther C A H Scheers; Guido Krenning; Berend van der Lei; Maaike H M Oonk; Joris A van Dongen
Journal:  Exp Dermatol       Date:  2022-03-16       Impact factor: 4.511

7.  Histological analysis of fat grafting with platelet-rich plasma for diabetic foot ulcers-A randomised controlled trial.

Authors:  Grant Switzer Nolan; Oliver John Smith; Susan Heavey; Gavin Jell; Afshin Mosahebi
Journal:  Int Wound J       Date:  2021-06-24       Impact factor: 3.315

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.